Potential to Develop Disease Treatments for Diabetic Kidney Disease and
Retinopathy, Each Multi-Billion-Dollar Drug Markets
JENKINTOWN, Pa., March 17 /PRNewswire/ -- Dynamis Therapeutics, Inc. announced the discovery of a new class of compounds that inhibit the production of RAGE, the Receptor for Advanced Glycation End Products (AGEs). Scientists expect that a RAGE inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer's, inflammatory diseases, some cancers, and aging.
A patent has been filed on the discovery.
A team of Dynamis Therapeutics' scientists significantly decreased kidney and retina RAGE in aged rats that were orally dosed with Dynamis Therapeutics' RAGE inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited RAGE in a variety of cells grown in culture.
In a parallel experiment, Dynamis Therapeutics' scientists increased the life span of mice by adding a RAGE inhibitor to their drinking water. The laboratory mice were divided into four groups: a control group treated only with water and three groups treated with varying doses of the RAGE inhibitor. The mice receiving the highest RAGE inhibitor dose lived, on average, 256 days longer than those receiving only water. Longevity increased proportionally with dosage strength.
Commented Dr. Annette Tobia, president and founder of Dynamis Therapeutics, Inc., "We are very excited about these results, since discovering RAGE inhibitors enables Dynamis Therapeutics to develop a treatment for diabetic kidney disease and blindness. Diabetes and its complications have become epidemic, not only in the United States, but worldwide. Retinopathy often leads to blindness. It would be a tremendous advance to eventually have a drug to treat such a serious disease."
Dynamis Therapeutics, Inc., located in Jenkintown, Penns
|SOURCE Dynamis Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved